Valentin Harter - Publications

Early mobilization with or without cycloergometry in patients with septic shock in Intensive Care Unit: a randomized controlled trial.

Journal: Annals of intensive care

Published: February 02, 2026

Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor.

Journal: European urology oncology

Published: September 02, 2025

The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors.

Journal: BMC cancer

Published: December 20, 2024

Time to reconsider the use of synthetic mesh in immediate prepectoral implant-based breast reconstruction: Impact of their use on short-term outcomes.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: April 15, 2024

Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 06, 2024

Perioperative chemotherapy in bladder cancer: the more cisplatin, the best survival?

Journal: World journal of urology

Published: January 20, 2024

Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.

Journal: The Journal of urology

Published: December 28, 2023

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.

Journal: BMC cancer

Published: July 17, 2023

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.

Journal: The Lancet. Oncology

Published: June 08, 2023

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.

Journal: Cancers

Published: February 14, 2023

ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies.

Journal: BMC cancer

Published: January 11, 2023

Reply to S. Zeng et al.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 15, 2022